A Final Word

REFERENCES

• McCarthy EJ, Perreault WD. Basic marketing: A managerial approach. 8th ed. Homewood, IL: R. D. Irwin; 1984.
   Google Scholar
• Goodrum C, Dalrymple H. Advertising in America, the first 200 years. New York: Harry N. Abrams; 1990.
   Google Scholar
• Study Commission on Pharmacy. Pharmacists for the future: The report of the Study Commission on Pharmacy. Ann Arbor, MI: Health Administration Press; 1975.
   Google Scholar
• Quoted in: Djerassi C. The politics of contraception. New York: W. W. Norton; 1979.
   Google Scholar
• Caldwell A. Origins of psychopharmacology from CPZ to LSD. Springfield, IL: Charles C. Thomas; 1970.
   Google Scholar
• Smith MC. Small comfort: A history of the minor tranquilizers. New York: Praeger; 1985.
   Google Scholar
• McEvilla JD. Pharmacy and the professional fee. J Am Pharm Assoc. 1962; N52(9):520–4.
   Google Scholar
• Olsen PC. Marketing drug products. New York: Topics Publishing; 1964.
   Google Scholar
• Firestone TM. A price index for drugs. Drug Cosmetic Industry. 1963; 87(4): 470.
   Google Scholar
• McEvilla JD. Price determination theory in the pharmaceutical industry. Drug Cosmetic Industry. 1958; 82(1):34.
   Google Scholar
• Lebhar GM. The story of drug chains. Chain Store Age. 1950; 25(6):2.
   Google Scholar
• Kelly ET, Palmer HA. Increasing OTC market share: Strategies for pharma-cists. Pharm Bus. 1993; 4(1):6–9.
   Google Scholar
• Hepler CD. Clozapine and the outmoded drug use process. Am Pharm. 1990; N530(12):39–40.
   Google Scholar
• Stolley P. Cultural lag in health care. Inquiry. 1971; 8:71–6.
   Google Scholar
• Johnson A, Mathews AW. Big pharma catches a chill, fearing Democrats' pre-scriptions on pricing. Wall Street J. 2006 Nov 9:C1.
   Google Scholar
• Harlow AM. Pharmaceutical marketing and the pubic in perspective. In: Wright JS, Goldstucker IL, eds. New ideas for successful marketing. Chicago: American Mar-keting Association; 1966:571–80.
   Google Scholar
• Apple WS. Speech of September 22, 1967, to U.S. Senate Finance Committee. Reported in A.Ph.A. Newsl. 1967; 6(Sept 23).
   Google Scholar
• Apple WS. Statement before Senate Subcommittee on Antitrust and Monopoly. J Am Pharm Assoc. 1967; NS7(Mar):111ff.
   Google Scholar
• Editorial. Fam Physician. 1967; 13(Oct):45.
   Google Scholar
• Davis DA. Not so lily-white druggists flee the kitchen. Drug Cosmetic Industry. 1967; 101(Oct):39.
   Google Scholar
• Squibb chief tells hearing why and how of drug pricing. Drug News Weekly. 1967; (Oct 16):10.
   Google Scholar
• Manischewitz DB, Stuart JA. Marketing under attack. J Marketing. 1962; 26(Jul): 1–6.
   Google Scholar
• Backman J. Advertising and competition. New York: New York University Press; 1967.
   Google Scholar
• Backman J. NAS finds few drugs ineffective, Goddard reports. Drug Trade News. 1967; 42(Oct 23): lff.
   Google Scholar
• Backman J. Squibb's Furlaud wins compliments from Nelson; first volunteer industry witness. Drug Trade News. 1967; 42(Oct 23): lff.
   Google Scholar
• Brock D. Quality of life measures in health care and medical ethics. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996:497–510.
   Google Scholar
• Patrick DL, Chiang YP. Measurement of health outcomes in treatment effec-tiveness evaluations: Conceptual and methodological challenges. Med Care. 2000; 38(9 Suppl): II14-II25.
   Google Scholar
• Burke LB. U.S. regulation of pharmaceutical outcomes research. Value in Health. 2001; 4:5–7.
   PubMedGoogle Scholar
• Spilker B. Multinational pharmaceutical companies: Principles and practices. 2nd ed. New York: Raven Press; 1994.
   Google Scholar
• Morris LA, Beckett TK, Lechter KJ. A marketing perspective: Theoretical un-derpinnings. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996:541–8.
   Google Scholar
• McHomey CA. Concepts and measurement of health status and health-related quality of life. In: Albrecht GL, Fitzpatrick R, Scrimshaw SC, eds. Handbook of social studies in health and medicine. Thousand Oaks, CA: SAGE Publications; 2000: 339–58.
   Google Scholar
• Ware JE. The status of health assessment 1994. Ann Rev Public Health. 1995;16:327–54.
   PubMedGoogle Scholar
• Lohr KN. Health outcomes methodology symposium: Summary and recom-mendations. Med Care. 2000; 38(9 Suppl):11194–11208.
   Google Scholar
• Bungay KM, Ware JE. Current concepts: Measuring and monitoring health-re-lated quality of life. Kalamazoo, MI: The Upjohn Company; 1993.
   Google Scholar
• Merck and Company. Merck corporate philanthropy. www.merck.com/over-view/philanthropy/ (accessed 2001 Mar 7).
   Google Scholar
• Eli Lilly and Company. Eli Lilly and Company Foundation Web page. www.lilly.com/about/community/foundation/index.html (accessed 2001 Mar 7).
   Google Scholar
• Angell M. The pharmaceutical industry-to whom is it accountable? N Engl J Med. 2000; 342:1902–4.
   Google Scholar
• Spilker B, Garbus SB. An industry perspective. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Pub-lishers; 1996:535–40.
   Google Scholar
• Shaw EH. Book review: New dimensions in marketing/quality of life research. J Macromarketing. 1997; 17:132–5.
   Google Scholar
• Leitzow HW. Challenge of the sixties. In: Gomez H, ed. Innovation-key to marketing progress. Chicago: American Marketing Association; 1963:577–85.
   Google Scholar
• Hampton C. Ethical drugs. Chemical Week. 1962; (Nov 7):138.
   Google Scholar
• Barber B. Drugs and society. New York: Russell Sage Foundation; 1967.
   Google Scholar
• Somers HM, Somers AR. Doctors, patients and health insurance. Washington: The Brookings Institution; 1962.
   Google Scholar